The therapeutic targets for psoriasis andtranslational medicine

Abstract

Psoriasis is an immune-mediated, chronic, inflammatory systemic disorder with a decrease onthe quality of life. The interleukin-23 (IL-23)/IL-17 axis plays a crucial role in the pathogenesis of psoriasis. Im‐mune cells and various cytokines are involved, including interferon-α (IFN-α), tumor necrosis factor-α (TNF-α),IFN-γ, IL-12, IL-22, IL-23 and IL-17. Based on elucidated pathogenesis, biologics targeting TNF-α, IL-23, andIL-17 have been approved in the treatment of psoriasis and achieved satisfying efficacy. However, it' s still farfrom complete cure. At present, more therapeutic targets are under research or in clinical trials, such as JAK-STATpathway, aryl hydrocarbon receptor and Rho-associated kinase. This review summarizes therapeutic targets andbiologics of psoriasis and provides a reference for the clinical transformation of promising therapeutic targets.

Keywords

• psoriasis
• il-23
• il-17
• jak inhibitor
• aryl hydrocarbon receptor
• clinical transformation